Hilal Zıvalı

Hilal Zıvalı

Auto-generated profile, based on publicly available information

Hilal Zıvalı

Department of Pharmaceutical Chemistry Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2026 in ChemMedChem
Verified
Journal Article
Open access
HSHasan Erdinç SELLİTEPE
Hasan Erdinç SELLİTEPE
AAAhmet Buğra Aksel
Ahmet Buğra Aksel
EYEzgi Pehlivanlar Yavrucu
Ezgi Pehlivanlar Yavrucu
HZHilal Zıvalı
Hilal Zıvalı
Begüm Nurpelin Sağlık ÖzkanBegüm Nurpelin Sağlık Özkan
Begüm Nurpelin Sağlık Özkan
İDİnci Selin DOGAN
İnci Selin DOGAN
Monoamine oxidase (MAO) catalyzes the breakdown of neurotransmitters, including serotonin, dopamine, and norepinephrine. There are two isoforms of this enzyme: MAO‐A and MAO‐B. MAO efficacy is widely investigated in neurodegenerative (MAO‐B) and depressive (MAO‐A) disorders. Upon examining the structures of known inhibitors, it becomes evident that many share an aliphatic amine structure. Furthermore, the literature suggests that compounds with naphthalene skeletons, phenolic structures, and hydrazone moieties exhibit MAO inhibitory activity. In this study, 12 N ‐acylhydrazone derivatives ( 5a–f , 6a–f ) were designed using ligand‐based design methods. Based on biological activity studies, the MAO‐A inhibition of the compounds was calculated to be 0.073–2.54 µM, and the MAO‐B inhibition was 0.064–3.147 µM. Among all compounds, the derivatives bearing a naphthalene ring ( 5d – f , 6d – f ) exhibited MAO enzyme inhibition at levels comparable to those of the reference compounds. The compound with the highest activity, 6e , had IC 50 values of 0.073 ± 0.002 and 0.064 ± 0.002 µM against MAO‐A and MAO‐B, respectively. Due to its superior potency against human MAO‐B, enzyme kinetic studies were further conducted on compound 6e . Consequently, the pronounced inhibitory potency, reversible competitive kinetics, and favorable pharmacokinetic profile of compound 6e designate it as a strong lead candidate for advanced preclinical evaluation.

14 July 2026 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
HSHasan Erdinç SELLİTEPE
Hasan Erdinç SELLİTEPE
AAAhmet Buğra Aksel
Ahmet Buğra Aksel
HZHilal Zıvalı
Hilal Zıvalı
EYEzgi Pehlivanlar Yavrucu
Ezgi Pehlivanlar Yavrucu
Begüm Nurpelin Sağlık ÖzkanBegüm Nurpelin Sağlık Özkan
Begüm Nurpelin Sağlık Özkan
KKKutsal Özcan Kosif
Kutsal Özcan Kosif